Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6891-6901

  Armstrong, A J ^a   Haggman M ^b   Stadler, W M ^c   Gingrich, J R ^d   Assikis, V ^e   Polikoff, J ^f   Damber, J E ^g   Belkoff, L ^h   Nordle, O ⁱ   Forsberg, G ⁱ   Carducci, M A ^j   Pili, R ^k  

^a DUKE CANCER INSTITUTE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Peachtree Hematology Oncology Consultants   (United States)

^f KAISER PERMANENTE MEDICAL CENTER   (United States)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h Urologic Consultants of SEPA   (United States)

ⁱ Active Biotech Research AB   (Sweden)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMYLASE; LACTATE DEHYDROGENASE; NARCOTIC ANALGESIC AGENT; PLACEBO; TASQUINIMOD; THROMBOSPONDIN 1; TRIACYLGLYCEROL LIPASE; TUMOR MARKER; VASCULOTROPIN A;

ABDOMINAL PAIN; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASYMPTOMATIC DISEASE; BACKACHE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; EXPLORATORY RESEARCH; FATIGUE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEADACHE; HEART INFARCTION; HUMAN; INFLAMMATION; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SURVIVAL TIME; SYMPTOM; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

BONE NEOPLASMS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; HUMANS; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUINOLINES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890583838     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1581     Document Type: Article

References (37)

1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for meta-static castration-resistant prostate cancer progressing after doce-taxel treatment: a randomised open-label trial. Lancet 2010;376: 1147-54.
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
3. Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351: 1502-12. (Pubitemid 39315317)
4. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de SP, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
7. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007;67:790-7. (Pubitemid 46709447)
8. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, et al. Identification of ABR-215050 as lead second generation quin-oline-3- carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006;66:1768-78. (Pubitemid 44893902)
9. Isaacs JT. The long and winding road for the development of tasqui-nimod as an oral second-generation quinoline-3-carboxamide anti-angiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs 2010;19:1235-43.
10. Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, Wikstrom P, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS ONE 2012;7:e34207.
11. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009;7:e97.
12. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
13. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angio-genic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010;9:107.
14. Cursiefen C, Maruyama K, Bock F, Saban D, Sadrai Z, Lawler J, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med 2011;208:1083-92.
15. Oka M, Iwata C, Suzuki HI, Kiyono K, Morishita Y, Watabe T, et al. Inhibition of endogenous TGF-beta signaling enhances lymphangio-genesis. Blood 2008;111:4571-9.
16. Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res 2013;73:1386-99.
17. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, et al. Phase II randomized, double-blind, placebo-controlled study of tas-quinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022-8.
18. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009;101:1233-40.
19. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
20. Armstrong AJ, Garrett-Mayer ES, Yang YC, de WR, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007;13:6396-403. (Pubitemid 350075029)
21. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7. (Pubitemid 46606398)
22. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009;16:940-52.
23. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
24. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28: 1099-105.
25. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-40.
26. Jennbacken K, Welen K, Olsson A, Axelsson B, Torngren M, Damber JE, et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate 2012;72:913-24.
27. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66. (Pubitemid 350036854)
28. Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012;118:5709-18.
29. Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore ND, De Souza PL, et al. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. J Clin Oncol (Meeting Abstracts) 2013;31:5.
30. Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, et al. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis. Arthritis Rheum 2011; 63:1365-75.
31. Zreiqat H, Howlett CR, Gronthos S, Hume D, Geczy CL. S100A8/S100A9 and their association with cartilage and bone. J Mol Histol 2007;38:381-91. (Pubitemid 350056770)
32. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
33. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 2010; 28:4510.
34. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch-and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22:373-88.
35. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immu-notherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 2013;81:1297-302.
36. Firlej V, Mathieu JR, Gilbert C, Lemonnier L, Nakhle J, Gallou-Kabani C, et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res 2011;71:7649-58.
37. Catena R, Bhattacharya N, El RT, Wang S, Choi H, Gao D, et al. Bone marrow-derived gr1+ cells can generate a metastasis-resistant micro-environment via induced secretion of thrombospondin-1. Cancer Discov 2013;3:578-89.